Minimal inhibitory concentrations of linezolid against clinical isolates of coryneform bacteria.
In order to evaluate the efficacy of linezolid for treating severe infections with coryneform bacteria, the activity of linezolid was tested in vitro against 425 clinically relevant isolates of coryneform bacteria and compared with the activity of penicillin and erythromycin. The minimal inhibitory concentration of linezolid did not exceed 2 microg/ml for any of the isolates tested, indicating that this agent has very good activity against coryneform bacteria. These results suggest linezolid is a possible alternative antimicrobial agent for the treatment of severe infections caused by coryneform bacteria.
Funke
G
G
Department of Medical Microbiology and Hygiene, Gärtner & Colleagues Laboratories, Elisabethenstrasse 11, 88212, Ravensburg, Germany. ldg.funke@t-online.de
Nietznik
C
C
D000081:Acetamides / Q000008:administration & dosage*; D000192:Actinomycetales / Q000187:drug effects* / Q000302:isolation & purification; D000193:Actinomycetales Infections / Q000188:drug therapy / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D006801:Humans; D066298:In Vitro Techniques; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000008:administration & dosage*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid